Printer Friendly

Molecular Characterization and Spoligotyping Analysis of Multi Drug Resistant Mycobacterium tuberculosis from a High TB Endemic Area of Pakistan.

Byline: Sajid Ali, Obaid Ullah, Muhammad Mumtaz Khan, M. Tahir Khan, Sajjad Ahmed, Anwar Sheed and Fariha Hassan

Abstract

Background: Multidrug resistant tuberculosis caused by Mycobacterium tuberculosis is an infection that is resistant to rifampicin and isoniazid. Management of Multidrug resistant tuberculosis is a serious challenge worldwide.

Objectives: To investigate hotspot mutations in rpoB, katG and inhA genes and its possible co-relation with predominant genotypes in Khyber Pakhtunkhwa, Pakistan.

Study design, settings and duration: This cross sectional study was conducted after approval from research and ethics committee of Provincial TB Control Program, Khyber Pakhtunkhwa in March 2015.

Materials and Methods: A total of 166 clinical isolates were analysed which were collected from programmatic management of drug-resistant tuberculosis units. All samples were characterized by phonotypical drug susceptibility test, genotypic drug resistant test (line probe assay) and spoligotyping analysis using 'TB-SPRINT' micro bead assay.

Results: Out of the total 166 samples, 97 strains were resistant to rifampicin (RIF) and 106 strains were resistant to isoniazid (INH). Most common mutation in rpoB was S531L in 75 (77%) isolates followed by D516V in 10 (10%) and H526Y in 6 (6%) samples respectively. A rare mutation in rpoB gene at codon 522 and deletion of codon 518 was also reported. In 106 INH resistant strains, 97(91%) were associated with mutation in katG gene while resistance in 9 (8.4%) strain was due to mutation in the inhA promoter region. Spoligotyping analysis revealed 55 distinct types of different patterns. Spoligotyping patterns of 146 samples matched with 15 different linage of M.tuberculosis in which 101 (60%) were identified as the predominant CAS1-Delhi linage. The pattern of 20 strains (12%) did not matched to any other pattern in the SITVIT database and were named orphan KP.

Conclusion: Molecular characterization of M.tuberculosis is very helpful in the early identification of MDR-TB. As CAS1-Delhi is the predominant type in this region, its association with drug resistance, treatment failure and patient demographic profiles should be investigated.

Key words: Spoligotyping, katG, rpoB, line probe assay, TB-SPRINT.

Introduction

The emergence of drug resistance in Mycobacterium tuberculosis (M.tuberculosis) is a serious global threat. Pakistan contributes about 65% of tuberculosis (TB) burden in the Eastern Mediterranean region and ranks 5th among the countries with high burden of TB. Prevalence of the TB is estimated as 342 cases in one million population or 670,000 cases per year.1 Rapid identification of drug resistance in M.tuberculosis is a hope to effectively treat and control this deadly disease. Tuberculosis (TB) is treated with first line drugs including streptomycin (STR), isoniazid (INH), rifampicin (RIF), ethambutol (ETB) and pyrazinamide (PZA). Two of these drugs INH and RIF kill more than 99% of the susceptible mycobacterial population.2 Rapid genotypical assays for drug susceptibility testing (DST) is gaining more popularity for its rapid results as the phonotypical DST takes 4-8 weeks.3

These assays target specific mutations responsible for drug resistance in M. tuberculosis like resistant to RIF is conferred by mutation in rpoB gene that codes for [beta]-subunit of RNA polymerase.4 More than 90% of mutation occur in specific region of this gene called rifampicin resistance determining region (RRDR) that is only 81 base pair long but contribute to more than 95% resistance to rifampicin.4,5 The predominant mutations reported in different molecular studies are Ser531Leu, His526Asp, His526Tyr and Asp516.

Resistance to INH is conferred by mutation in katG, inhA, ndh, kasA and ahpC-oxyR gene. However, 50 to 95% of INH resistance is associated with mutation in katG gene. The most common reported mutation is Ser315Thr substitution. Similarly, 15 to 30% of INH resistance is due to mutation in inhA promoter region at upstream position -15. The most common mutation in the inhA promoter is C8T substitution.6 GenoTypeA(r) MTBDR plus (Hain Life-Science, Nehren, Germany) is one of the two line probe assay (LPA) that detects common mutations in rpoB, katG and inhA promoter region. Mutation in the RRDR region of rpoB is detected using 8 wild type immobilized probes along with 4 other probes that detect most common substitution at codon 516, 526 and 531 as in Figure-1.7 Each probe binds to its corresponding complementary codon.

In the same way one wild type and two mutated probes are used to determine mutation at codon 315 of katG while two wild type probes and four mutation probes are used to detection mutation at -16, -15 and -8 upstream region of inhA.8

Spoligotyping stands for spacer oligonucleotide typing that is a technique used for simultaneously detection and typing of M.tuberculosis. It is a PCR based technique that amplify direct repeat locus (DR) along with the neighboring spacer in the Mycobacterium genome.9

TB-SPRINT is commercial assay used for determining DNA polymorphism at the DR locus and simultaneously detects mutation in RRDR region of rpoB gene.10

The aim of the present study is to investigate hotspot mutations in rpoB, katG and inhA genes and its possible co-relation with predominant genotypes in the region.

Materials and Methods

This cross sectional study involved 166 pulmonary samples that were positive after smear microscopy on ziehl neelsen (ZN) technique. All the received samples were digested and decontaminated using standard N-acetyl-L-cysteine sodium hydroxide (NALC-NaOH) method 11 in a biosafety level 3 facility (BSLIII) at Provincial TB Reference Laboratory, Peshawar. Decontaminated samples were inoculated on Lowenstein Jensen medium (LJ) and mycobacterium growth indicator tube (MGIT). Positive growth in the tubes was confirmed by Tbc ID device (Ref: 245159, Becton, Dickinson). All confirmed mycobacterial isolates were processed for both phonotypical DST and molecular resistance assay. Drug susceptibility test (DST) was carried out using BD BACTEC MGIT 960 SIRE kit (Ref: 245123, Becton, Dickinson) in which final drug concentration was 1ug/ml for RIF and 0.1 ug/ml for INH drug.

Line probe assay (LPA) was performed for the detection of molecular resistance using GenoTypeA(r) MTBDR plus assay (Ref: 30496, Hain Lifescience, Germany). Mutations were confirmed by sequencing respective genes using primers previously described by Talenti et al.12 Briefly, 1 mL of each positive isolate was centrifuged at 1000 gx for 15 minutes. Supernatant was discarded and 100uL DNAs free molecular grade water was added to re-suspend the pallets. Suspension was then heat inactivated followed by sonication for 15 minutes and final centrifugation at13000 gx for 5 minutes.PCR mixture was constituted by mixing 5 uL of DNA templates and 45 uL of multiplex PCR reagent provided with the assay. PCR reaction was programmed as per manufacturer instruction.

Finally 20 uL of the amplified product (Figure-2) was then hybridized to the DNA strips immobilized with specific probes. Results were interpreted as per manufacturer instructions while sensitivity and specificity was performed using Medcalc software (https://www.medcalc.org). Spoligotyping study was done at institute de Genetique et Microbiologie, Universite Paris-Sud using TB-SPRINT assay running on microbead-based multiplexed systems (Luminex 200) and result were interpreted at SITVIT database.13

The study was conducted after approval from research and ethics committee of Provincial TB Control Program, Khyber Pakhtunkhwa (TB/KP/RandD-25-15) in March 2015.

Results

A total of 166 mycobacterium isolates were tested for both DST and LPA assay. DST identified 97 (57 %) isolates resistant to RIF and 129 (77%) isolates resistant to INH. LPA identified all 97 (100%) rifampicin resistant mutant and 106 (82%) INH mutant and could not detect 23 (18%) isolates that were phenotypically resistant to INH. Resistance in these strains suggests mutation in other genes that confer resistance to INH but not target in LPA.

In the current study 97 (61%) of strains showed mutation in RRDR region. Most frequent mutation in rpoB was S531L in 75 (77%) isolates, D516V in 10 (10%) isolates and H526Y in 6 (6%) isolates respectively. Less frequent mutations were L511P and S522L. Deletion of one codon was also observed at position 518 in an isolate associated with RIF resistance (Table-1).

Among 106 INH resistant isolates, 97(91%) were associated with katG mutation while 24 (22%) with promoter region of inhA. The predominant mutation in katG was S315T in 97 (100%) strains confirmed by MUT1 and MUT2 probes of LPA assay (Table-2). Mutation in inhA was shown in 24 (22%) isolates. The most frequent mutation was C15T in 20 (83%) isolates followed by T8C mutation in 4 (17%) isolates (Table-3). Analysis showed that InhA mutations was associated with mutation in katG in 15 strains while only 9 isolates were causing INH resistant without any association with katG gene.

All samples produce valid spoligotype patterns of which 146 (88%) matched to known pattern of 15 clads while pattern of 20 (12%) remained unmatched in the SITVIT database and were declared as new types. Sublineage of Common Asian Strain was the predominant genotype family in 121 (82%) samples, followed by Beijing in 9 (6%) and T1 in 7 (5%) samples. Frequency of MDR was higher among Beijing 8 (89%) while 41 (41%) strains were MDR in CAS1-Delhi family. A brief summary of drug resistance corresponding to each genotype along with MDR frequency in each genotype is given in Figure-3.

Table 1: Mutation analysis of rpoB gene with corresponding probes. A total of eight wild type and three mutational probes are used that binds to complementary sequences on mycobacterial DNA. Absence of any probes after hybridization corresponds to a confirm mutation.

Codon###Probe Name###Frequency of Missing###Mutation Confirmed###Probe Used for Mutations###Frequency Mutation

Analyzed###Probe n (%)###n (%)

505-509###rpoB WT1###0

510-513###rpoB WT2###1 (1)###L511P###1 (1)

510-517###rpoB WT2/WT3###0

513-519###rpoB WT3/WT4###13 (13.4)###D516V###MUT1###10 (10)

###D516V

516-522###rpoB WT4/WT5###1 (1)###Deletion:518###1 (1)

518-525###rpoB WT5/WT6###1 (1)###S522L

526-529###rpoB WT7###6 (6.3)###H526Y###MUT2A/ MUT2B###6 (6.3)

530-533###rpoB WT8###75 (77.3%)###S531L###MUT3###75 (77.3)

Table 2: Mutation analysis of katG gene. A total of three probes are used in the assay. Each corroding to a specific mutation.

Codon###Probe###Frequency of Missing Probe %###Specific###Probe Used for Mutations###Frequency Mutation %

Analyzed###Name###Mutation

315###katG WT###97 (100%)###S315T1###MUT1###94 (97%)

###S315T2###MUT2###03 (3%)

Table 3: Mutation analysis of inhA gene with corresponding probes.

Nucleic Acid###Probe Name###Frequency of###Specific Mutation###Mutation Probe###Frequency Mutation

Position Analyzed###Missing Probe###n (%)

###n (%)

-15/-16###inhA WT1###20(82.6)###C15T###inhA MUT1###20 (82.6)

###A16G###inhA MUT2

-8###inhA WT2###4(17.3)###T8C###inhA MUT3A###4 (17.3)

###T8A###inhA MUT3B

Analysis showed that Beijing and CAS strains are more likely associated with drug resistance (chi square test, p =0.001; CI=95).

Discussion

MTBDR plus assay is one of the two LPA technologies that is endorsed by WHO in 2008 for the rapid detection MDR-TB in smear positive samples and positive colonies from culture growth. The assay has 95-98% sensitivity and specificity to detect RIF resistance while its sensitivity and specificity to detect INH resistance varies from 57 to 100%.14

Sensitivity of MTBDR plus assay has been evaluated in early studies ranging from 67 to 97%.15,16 In this study the assay showed 100% sensitivity and 98% specificity to detect RIF resistance while it was 82% sensitive and 100% specific to detect INH resistance. These finding are in accordance with farooqi et al.15 who has reported 92.5% sensitivity and 98.2% specificity to detect RIF resistance while for INH resistance sensitivity and specificity was 76.6% and 100% respectively. In our study the most frequent mutation in rpoB was (77%) at codon 531, 13% at codon 516 and 6%at codon 526. These finding were concordant with the results of previous studies.17-19

Khan et al. has also reported 52%, 15% and 7% mutation at codon 531, 526 and 516 respectively that are agreed with the current study.20 In this study we observed deletion of codon 518 that is rarely reported and not likely detected by LPA assay in previous studies from Pakistan although reported elsewhere.15,21 Two other rare mutations at codons 522 and 511 were also observed in the current study. In these findings serine was substituted by leucin (TCG->TTG) at codon 522 while leucine was substituted by proline (CTG->CCG) at position 511. Silent mutation at 511 has been reported in two early studies.20

We are therefore reporting a missense mutation (L511P) and a substitution S522L that was never reported from Pakistan before. Multiple probes are used in LPA to detect both high-level (mutations) and low level INH resistance in this study MTBDR plus failed to detect 17% (n=23) isolates that were resistant to INH. Resistance in these strains may be contributed to mutation other genes that confer resistance to INH but not target in LPA assay.22

However, the reported 84% mutation of S315T in katG is concordant with the result of farooqi et al 15 who reported 66.1% mutation and Ali et al.23 reported 63% of mutation. Similarly our finding of 8% contribution to INH resistance by mutation in inhA gene is consistent with other study by farooqi et al.15 who found 11.9% mutation in inhA. In the current study it was shown 80 (83%) inhA mutation was contributed to transition of C to T at position -15 and 17.3% was due to T to C transition at position-8 in the promoter region of inhA gene.

Spoligotyping analysis of the current study revealed that CAS-1 Delhi is the predominant genotype 60% in Khyber Pakthunkhwa. It was confirmed that Beijing genotype was less dominant 5% that is consistent to other studies.18,24,25 Furthermore, Beijing strains do not contribute too much to MDR-TB incidence because of its low prevalence in this region although the MDR-TB is more likely associated with Beijing strain. In this study 20 spoligo patterns did not match any of the previously published patterns in SITVIT database. Further study will reveal the fact of its diversity and its relation to new and recurrent infection.

Molecular epidemiology of M.tuberculosis was uncovered for the first time in Khyber Pakhtunkhwa, which is a highly TB endemic area of Pakistan. Molecular characterization of M. tuberculosis is very helpful in the early identification of MDR-TB.

As Common Asian Strain (CAS1 Dehli) is the predominant type in this region. It is therefore recommended to study association with drug resistance, treatment failure and patient demographic profiles should be investigated in much detail.

Acknowledgement

We are thankful to Professor Christophe Sola and Harrison Magdinier for facilitating spoligotyping analysis at Universite Paris-Sud, France. We extend our gratitude to Pakistan Health Research Council, KMC Peshawar for technical facilitation.

Conflict of interest: None declared.

References

1. WHO. Global tuberculosis report 2014. WHO/HTM/TB/2014.08. ISBN: 9789241564809. (Accessed on 15th March 2018) Available from URL:http://www.who.int/tb/publications/global_report/en/. 2014 [cited 2015 Jul 27].

2. De Steenwinkel JEM, de Knegt GJ, ten Kate MT, van Belkum A, Verbrugh HA, Kremer K, et al. Time-kill kinetics of anti-tuberculosis drugs, and emergence of resistance, in relation to metabolic activity of Mycobacterium tuberculosis. J Antimicrob Chemother 2010; 65(12): 2582-9.

3. WHO. Implementing tuberculosis diagnostics: A policy framework . WHO; p 39. (Accessed on 15th March 2018) Available from URL: http://apps.who.int/iris/bitstream/10665/162712/1/978 9241508612_eng.pdf?ua=1andua=1

4. Heep M, Brandstatter B, Rieger U, Lehn N, Richter E, Rusch-Gerdes S, et al. Frequency of rpoB Mutations Inside and Outside the Cluster I Region in Rifampin-Resistant Clinical Mycobacterium tuberculosis Isolates. J Clin Microbiol 2001; 39(1): 107-10.

5. Kozhamkulov U, Akhmetova A, Rakhimova S, Belova E, Alenova A, Bismilda V, et al. Molecular characterization of rifampicin- and isoniazid-resistant Mycobacterium tuberculosis strains isolated in Kazakhstan. Jpn J Infect Dis 2011; 64(3): 253-5.

6. Tracevska T, Jansone I, Broka L, Marga O, Baumanis V. Mutations in the rpoB and katG Genes Leading to Drug Resistance in Mycobacterium tuberculosis in Latvia. J Clin Microbiol 2002; 40(10): 3789-92.

7. Hillemann D, Weizenegger M, Kubica T, Richter E, Niemann S. Use of the genotype MTBDR assay for rapid detection of rifampin and isoniazid resistance in Mycobacterium tuberculosis complex isolates. J Clin Microbiol 2005; 43(8): 3699-703.

8. Hillemann D, Rusch-Gerdes S, Richter E. Evaluation of the GenoType MTBDRplus assay for rifampin and isoniazid susceptibility testing of Mycobacterium tuberculosis strains and clinical specimens. J Clin Microbiol 2007; 45(8): 2635-40.

9. He L, Fan X, Xie J. Comparative genomic structures of Mycobacterium CRISPR-Cas. J Cell Biochem 2012; 113(7): 2464-73.

10. Gomgnimbou MK, Hernandez-Neuta I, Panaiotov S, Bachiyska E, Palomino JC, Martin A, et al. Tuberculosis-Spoligo-Rifampin-Isoniazid Typing: an All-in-One Assay Technique for Surveillance and Control of Multidrug-Resistant Tuberculosis on Luminex Devices. J Clin Microbiol 2013; 51(11): 3527-34.

11. GLI GLI. Mycobacteriology Laboratory Manual . First Edition. 2014. p. 147. (Accessed on 15th March 2018) Available from URL: http://www.who. int/tb/laboratory/mycobacteriology-laboratory-manual.pdf

12. Telenti A, Honore N, Bernasconi C, March J, Ortega A, Heym B, et al. Genotypic assessment of isoniazid and rifampin resistance in Mycobacterium tuberculosis: a blind study at reference laboratory level. J Clin Microbiol 1997; 35(3): 719-23.

13. Demay C, Liens B, Burguiere T, Hill V, Couvin D, Millet J, et al. SITVITWEB - A publicly available international multimarker database for studying Mycobacterium tuberculosis genetic diversity and molecular epidemiology. Infect Genet Evol 2012; 12(4): 755-66.

14. WHO. Molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis. Geneva, Switzerland: World Health Organization; 2008. (Accessed on 15th March 2018) Available from URL: http://www.who.int/tb/features_archive/policy_statement.pdf

15. Farooqi JQ, Khan E, Alam SMZ, Ali A, Hasan Z, Hasan R. Line probe assay for detection of rifampicin and isoniazid resistant tuberculosis in Pakistan. J Pak Med Assoc 2012; 62(8): 767-72.

16. Miotto P, Piana F, Penati V, Canducci F, Migliori GB, Cirillo DM. Use of Genotype MTBDR Assay for Molecular Detection of Rifampin and Isoniazid Resistance in Mycobacterium tuberculosis Clinical Strains Isolated in Italy. J Clin Microbiol 2006; 44(7): 2485-91.

17. Brossier F, Veziris N, Truffot-Pernot C, Jarlier V, Sougakoff W. Performance of the genotype MTBDR line probe assay for detection of resistance to rifampin and isoniazid in strains of Mycobacterium tuberculosis with low- and high-level resistance. J Clin Microbiol 2006; 44(10): 3659-64.

18. Yasmin M, Gomgnimbou MK, Siddiqui RT, Refregier G, Sola C. Multi-drug resistant Mycobacterium tuberculosis complex genetic diversity and clues on recent transmission in Punjab, Pakistan. Infect Genet Evol 2014; 27: 6-14.

19. Viader-Salvado JM, Luna-Aguirre CM, Reyes-Ruiz JM, Valdez-Leal R, del Bosque-Moncayo M de los A, Tijerina-Menchaca R, et al. Frequency of mutations in rpoB and codons 315 and 463 of katG in rifampin- and/or isoniazid-resistant Mycobacterium tuberculosis isolates from northeast Mexico. Microb Drug Resist Larchmt N 2003; 9(1): 33-8.

20. Khan SN, Niemann S, Gulfraz M, Qayyum M, Siddiqi S, Mirza ZS, et al. Molecular characterization of multidrug-resistant isolates of Mycobacterium tuberculosis from patients in Punjab, Pakistan. Pak J Zool 2013; 45(1): 93-100.

21. Causse M, Ruiz P, Gutierrez-Aroca JB, Casal M. Comparison of Two Molecular Methods for Rapid Diagnosis of Extrapulmonary Tuberculosis. J Clin Microbiol 2011; 49(8): 3065-7.

22. Hazbon MH, Brimacombe M, Bobadilla del Valle M, Cavatore M, Guerrero MI, Varma-Basil M, et al. Population Genetics Study of Isoniazid Resistance Mutations and Evolution of Multidrug-Resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 2006; 50(8): 2640-9.

23. Ali A, Hasan Z, Moatter T, Tanveer M, Hasan R. M. tuberculosis Central Asian Strain 1 MDR isolates have more mutations in rpoB and katG genes compared with other genotypes. Scand J Infect Dis 2009; 41(1): 37-44.

24. Hasan Z, Tanveer M, Kanji A, Hasan Q, Ghebremichael S, Hasan R. Spoligotyping of Mycobacterium tuberculosis Isolates from Pakistan Reveals Predominance of Central Asian Strain 1 and Beijing Isolates. J Clin Microbiol 2006; 44(5): 1763-8.

25. 25. Tanveer M, Hasan Z, Siddiqui AR, Ali A, Kanji A, Ghebremicheal S, et al. Genotyping and drug resistance patterns of M. tuberculosis strains in Pakistan. BMC Infect Dis 2008; 8(1): 171.
COPYRIGHT 2018 Asianet-Pakistan
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:tuberculosis
Publication:Pakistan Journal of Medical Research
Article Type:Report
Geographic Code:9PAKI
Date:Mar 31, 2018
Words:3560
Previous Article:Impact of Socio-Demographic Characteristics on Sleep Quality and Health of Insomnia Patients.
Next Article:Impact of Cancer-Related Fatigue on Psychological Semiology among Cancer Patients.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters